{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-24-000066","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.172106+00:00","generated_at":"2026-05-31T20:39:15.741289+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash","bullets":["Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.","Consideration of ~$300M in cash; expected closing by end of 2024.","Innovalve to join TMTT product group; initial investment made in 2017.","Edwards' SAPIEN M3 TMVR system on track for European approval by end of 2025.","Acquisition aims to expand treatable mitral valve population with combined platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-24-000066","json":"https://secwatch.observer/filing/0001099800-24-000066.json","markdown":"https://secwatch.observer/filing/0001099800-24-000066.md","text":"https://secwatch.observer/filing/0001099800-24-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000066/0001099800-24-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000066/ew-20240715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:39:15.741289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}